Printer Friendly

PHARMOS TECHNOLOGY NAMED ONE TOP 10 MEDICAL ADVANCES OF 1992

 NEW YORK, March 30 /PRNewswire/ -- Pharmos Corporation (NASDAQ: PARS) today announced its technology to deliver drugs to the brain through a unique packaging system has been cited as one of the top 10 medical advances of 1992 by the Harvard Health Letter, a publication of the Harvard Medical School.
 "This technology allows drugs to be transported through the brain's natural protective barrier, one of the most challenging aspects of developing drugs for the eye and central nervous system," said the inventor of the technology Nicholas Bodor, Ph.D., director of the Center for Drug Discovery at the University of Florida College of Pharmacy. The discovery was featured in an article published last fall in the journal Science. "This is one of the first and only successful demonstrations of transporting a pain-killer peptide through this barrier, which is designed to shut out invading proteins."
 Pharmos has licensed from the University of Florida part of this technology and is actively developing drugs based on it. The company is currently in negotiations to extend its license to include Bodor's recent advances in the technology. Dr. Border is a member of Pharmos' Scientific Advisory Board and a director of the company.
 Technologies developed by Dr. Bodor also formed the basis of some of Pharmos' products currently in development, including Loteprednol etabonate currently in Phase III trials for ocular inflammation, Adaprolol Maleate in Phase I/II trials for glaucoma and Estradiol CDS in Phase I/II trials for post menopausal central nervous system conditions.
 Medical advances of 1992 were evaluated and ranked by the Harvard Health Letter's physician advisory board. Members weighed the significance of research findings based on their potential for having the greatest long-range impact on human health and disease.
 "This innovative strategy for getting drugs into the brain could open the door to a host of new treatments for pain, as well as for other conditions that involve the central nervous system," the Harvard authors said in the March 1993 edition.
 "This cutting edge technology brings Pharmos to the forefront of innovative medicine and complements our existing portfolio of drug delivery products," said Haim Aviv, Ph.D., chairman and chief executive officer of Pharmos.
 Pharmos Corporation is a pharmaceutical company engaged in the development of innovative therapeutic products to treat disorders of the eye, and central nervous system. The company utilizes a variety of unique and proprietary technologies to provide effective new modes of delivery and enhanced levels of specificity for existing pharmaceutical compounds.
 -0- 3/30/93
 /CONTACT: Stephen R. Streber, president and chief operating officer of Pharmos Corporation, 212-838-0087, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, or Donald C. Weinberger of Strategic Growth International, 212-826-9622, both for Pharmos/
 (PARS)


CO: Pharmos Corporation ST: New York IN: MTC SU:

TS-OS -- NY023 -- 0909 03/30/93 09:36 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1993
Words:471
Previous Article:THE BOMBAY COMPANY, INC. ANNOUNCES 26 PERCENT SALES INCREASE FOR MARCH
Next Article:THE FEDERAL RESERVE BANK OF BOSTON SIGNS AGREEMENT WITH BANCTEC TO DEVELOP IMAGE-BASED CHECK ARCHIVAL PROTOTYPE SYSTEM
Topics:


Related Articles
PHARMOS RECEIVES NATIONAL INSTITUTES OF HEALTH GRANT
PHARMOS COMPLETES $65 MILLION MERGER OF PHARMATEC; TO FOCUS EXPANDED TECHNOLOGY BASE ON DEVELOPMENT/COMMERCIALIZATION OF DRUGS FOR EYES,BRAIN
PHARMOS RESEARCHERS PRESENT DATA ON HU-211 AS A NEUROPROTECTANT IN STROKE AND HEAD TRAUMA
PHARMOS CORPORATION SIGNS BROAD LICENSE AGREEMENT WITH KEY DRUG DELIVERY SCIENTIST AND THE UNIVERSITY OF FLORIDA
PHARMOS ANNOUNCES THE SUCCESSFUL COMPLETION OF PHASE III CLINICAL TRIALS FOR LOTEMAX
PHARMOS ANNOUNCES SUBMISSION OF CHEMISTRY, MANUFACTURING AND CONTROL SECTION OF LOTEMAX NEW DRUG APPLICATION (NDA) TO FDA
PHARMOS ANNOUNCES SUBMISSION OF CHEMISTRY, MANUFACTURING AND CONTROL SECTION OF LOTEMAX NEW DRUG APPLICATION (NDA) TO FDA
PHARMOS SUBMITTED LOTEMAX CLINICAL PACKAGE TO FDA ADDRESSING $500 MILLION MARKET
PHARMOS SCIENTISTS PRESENT ENCOURAGING PRECLINICAL RESULTS ON NEW DRUG TO TREAT BREAST CANCER
PHARMOS PRESENTS LOTEMAX CLINICAL RESULTS AT ARVO CONVENTION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters